2014
Targeted agents: management of dermatologic toxicities.
Burtness B. Targeted agents: management of dermatologic toxicities. Journal Of The National Comprehensive Cancer Network 2014, 12: 793-6. PMID: 24853219, DOI: 10.6004/jnccn.2014.0192.Peer-Reviewed Original ResearchConceptsEpidermal growth factor receptor inhibitorsGrowth factor receptor inhibitorsDermatologic side effectsQuality of lifeDermatologic toxicitiesCutaneous complicationsSkin complicationsTherapeutic mainstayReceptor inhibitorsCommon culpritsToxicity profileMTOR inhibitorsSide effectsCosmetic issuesAnticancer treatmentPotential infectionComplicationsTreatmentInhibitorsTherapyAgentsCancerInfectionMainstayBRAF
2007
Clinical use of monoclonal antibodies to the epidermal growth factor receptor in colorectal cancer.
Burtness B. Clinical use of monoclonal antibodies to the epidermal growth factor receptor in colorectal cancer. Oncology 2007, 21: 964-70; discussion 970, 974, 976-7. PMID: 17715697.Peer-Reviewed Original ResearchConceptsEpidermal growth factor receptorColorectal cancerGrowth factor receptorChemotherapy-refractory colorectal cancerMonoclonal antibodiesFront-line therapyUse of cetuximabFactor receptorPredictors of responseClinical useCancerPromising novelPanitumumabSuch agentsTherapyAntibodiesReceptorsCetuximabAgentsDisease